148 related articles for article (PubMed ID: 10874215)
1. Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice.
Sato N; Saga T; Sakahara H; Nakamoto Y; Zhao S; Kuroki M; Iida Y; Endo K; Konishi J
Jpn J Cancer Res; 2000 Jun; 91(6):622-8. PubMed ID: 10874215
[TBL] [Abstract][Full Text] [Related]
2. Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma.
Li GP; Wang YX; Huang K; Zhang H; Zhang CF
World J Gastroenterol; 2005 Apr; 11(13):1917-21. PubMed ID: 15800980
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
[TBL] [Abstract][Full Text] [Related]
4. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.
Li GP; Zhang H; Zhu CM; Zhang J; Jiang XF
World J Gastroenterol; 2005 Oct; 11(40):6288-94. PubMed ID: 16419157
[TBL] [Abstract][Full Text] [Related]
5. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
6. Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity.
Kobayashi H; Sakahara H; Endo K; Yao ZS; Toyama S; Konishi J
Eur J Cancer; 1995 Sep; 31A(10):1689-96. PubMed ID: 7488426
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
8. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
[TBL] [Abstract][Full Text] [Related]
9. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells.
Li XF; Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1669-74. PubMed ID: 12458402
[TBL] [Abstract][Full Text] [Related]
10. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.
Yao Z; Zhang M; Kobayashi H; Sakahara H; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1995 May; 36(5):837-41. PubMed ID: 7738661
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96.
Chen JQ; Strand SE; Tennvall J; Lindgren L; Hindorf C; Sjögren HO
J Nucl Med; 1997 Dec; 38(12):1934-9. PubMed ID: 9430473
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the chase effects of avidin, streptavidin, neutravidin, and avidin-ferritin on a radiolabeled biotinylated anti-tumor monoclonal antibody.
Kobayashi H; Sakahara H; Endo K; Hosono M; Yao ZS; Toyama S; Konishi J
Jpn J Cancer Res; 1995 Mar; 86(3):310-4. PubMed ID: 7744702
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy for liver micrometastases in mice: pharmacokinetics, dose estimation, and long-term effect.
Saga T; Sakahara H; Nakamoto Y; Sato N; Zhao S; Iida Y; Kuroki M; Endo K; Konishi J
Jpn J Cancer Res; 1999 Mar; 90(3):342-8. PubMed ID: 10359050
[TBL] [Abstract][Full Text] [Related]
14. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor.
Kobayashi H; Sakahara H; Hosono M; Yao ZS; Toyama S; Endo K; Konishi J
J Nucl Med; 1994 Oct; 35(10):1677-84. PubMed ID: 7931671
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
17. Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody.
Zhang M; Sakahara H; Yao Z; Saga T; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
Nucl Med Biol; 1997 Jan; 24(1):61-4. PubMed ID: 9080476
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
19. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
20. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.
Buchegger F; Allal AS; Roth A; Papazyan JP; Dupertuis Y; Mirimanoff RO; Gillet M; Pelegrin A; Mach JP; Slosman DO
Anticancer Res; 2000; 20(3B):1889-96. PubMed ID: 10928122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
